BioCentury | Oct 27, 2020
Distillery Therapeutics
UCSF team develops trivalent binder of SARS-CoV-2 spike for COVID-19
...the ACE2-SARS-CoV-2 S interaction in preclinical testing for COVID-19 include: a camelid neutralizing single-domain antibody from Abcore Inc....
